文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

结缔组织病相关间质性肺疾病的肺部影像学模式影响预后和免疫抑制反应。

Lung imaging patterns in connective tissue disease-associated interstitial lung disease impact prognosis and immunosuppression response.

机构信息

Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

Department of Medicine, McGill University, Montreal, QC, Canada.

出版信息

Rheumatology (Oxford). 2024 Oct 1;63(10):2734-2740. doi: 10.1093/rheumatology/keae076.


DOI:10.1093/rheumatology/keae076
PMID:38336872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11443038/
Abstract

OBJECTIVES: Interstitial lung disease (ILD) in CTDs has highly variable morphology. We aimed to identify imaging features and their impact on ILD progression, mortality, and immunosuppression response. METHODS: Patients with CTD-ILD had high-resolution chest CT (HRCT) reviewed by expert radiologists blinded to clinical data for overall imaging pattern [usual interstitial pneumonia (UIP); non-specific interstitial pneumonia (NSIP); organizing pneumonia (OP); fibrotic hypersensitivity pneumonitis (fHP); and other]. Transplant-free survival and change in percent-predicted forced vital capacity (FVC) were compared using Cox and linear mixed-effects models adjusted for age, sex, smoking, and baseline FVC. FVC decline after immunosuppression was compared with pre-treatment. RESULTS: Among 645 CTD-ILD patients, the most frequent CTDs were SSc (n = 215), RA (n = 127), and inflammatory myopathies (n = 100). NSIP was the most common pattern (54%), followed by UIP (20%), fHP (9%), and OP (5%). Compared with the case for patients with UIP, FVC decline was slower in patients with NSIP (by 1.1%/year, 95% CI 0.2, 1.9) or OP (by 3.5%/year, 95% CI 2.0, 4.9), and mortality was lower in patients with NSIP [hazard ratio (HR) 0.65, 95% CI 0.45, 0.93] or OP (HR 0.18, 95% CI 0.05, 0.57), but higher in fHP (HR 1.58, 95% CI 1.01, 2.40). The extent of fibrosis also predicted FVC decline and mortality. After immunosuppression, FVC decline was slower compared with pre-treatment in NSIP (by 2.1%/year, 95% CI 1.4, 2.8), with no change for UIP or fHP. CONCLUSION: Multiple radiologic patterns are possible in CTD-ILD, including a fHP pattern. NSIP and OP were associated with better outcomes and response to immunosuppression, while fHP had worse survival compared with UIP.

摘要

目的:结缔组织病相关间质性肺病(CTD-ILD)的形态学表现具有高度异质性。本研究旨在明确影像学特征及其对ILD 进展、死亡率和免疫抑制反应的影响。

方法:由 2 名对临床数据不知情的胸部影像学专家对 CTD-ILD 患者的高分辨率胸部 CT(HRCT)进行评估,评估内容包括整体影像学模式[普通型间质性肺炎(UIP);非特异性间质性肺炎(NSIP);机化性肺炎(OP);纤维化型过敏性肺炎(fHP);其他]。采用 Cox 比例风险回归模型和线性混合效应模型比较无移植生存率和用力肺活量(FVC)的预计百分比变化,模型调整了年龄、性别、吸烟和基线 FVC。比较免疫抑制治疗前后 FVC 的下降情况。

结果:在 645 名 CTD-ILD 患者中,最常见的结缔组织病是系统性硬化症(SSc,n=215)、类风湿关节炎(RA,n=127)和炎症性肌病(n=100)。最常见的影像学模式是 NSIP(54%),其次是 UIP(20%)、fHP(9%)和 OP(5%)。与 UIP 患者相比,NSIP 患者的 FVC 下降速度较慢(每年 1.1%,95%CI 0.2,1.9),OP 患者的 FVC 下降速度较快(每年 3.5%,95%CI 2.0,4.9),NSIP 患者的死亡率较低(风险比[HR]0.65,95%CI 0.45,0.93),OP 患者的死亡率较低(HR 0.18,95%CI 0.05,0.57),fHP 患者的死亡率较高(HR 1.58,95%CI 1.01,2.40)。纤维化程度也预测 FVC 下降和死亡率。与治疗前相比,免疫抑制治疗后 NSIP 患者的 FVC 下降速度较慢(每年 2.1%,95%CI 1.4,2.8),而 UIP 或 fHP 患者的 FVC 下降速度无明显变化。

结论:CTD-ILD 可能存在多种影像学模式,包括 fHP 模式。NSIP 和 OP 与更好的预后和免疫抑制反应相关,而 fHP 与 UIP 相比,生存率更差。

相似文献

[1]
Lung imaging patterns in connective tissue disease-associated interstitial lung disease impact prognosis and immunosuppression response.

Rheumatology (Oxford). 2024-10-1

[2]
Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.

Kaohsiung J Med Sci. 2019-3-26

[3]
Pathological features of connective tissue disease-associated interstitial lung disease in transbronchial cryobiopsies.

Histopathology. 2025-1

[4]
Lung-Dominant Connective Tissue Disease: Clinical, Radiologic, and Histologic Features.

Chest. 2015-12

[5]
Rituximab in connective tissue disease-associated interstitial lung disease.

Clin Rheumatol. 2019-4-23

[6]
Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?

Chron Respir Dis. 2011

[7]
The potential utility of anterior upper lobe honeycomb-like lesion in interstitial lung disease associated with connective tissue disease.

Respir Med. 2020-10

[8]
Chest CT imaging features for prediction of treatment response in cryptogenic and connective tissue disease-related organizing pneumonia.

Eur Radiol. 2020-2-10

[9]
High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival.

Respir Med. 2017-5

[10]
Spectrum of high-resolution computed tomography pattern in lungs in patients with connective tissue disorders.

Ann Afr Med. 2023

引用本文的文献

[1]
Clinical, radiologic, and serologic predictors of rheumatic disease in interstitial lung disease patients.

Clin Rheumatol. 2025-6-11

[2]
Serum inflammatory markers as predictors of therapeutic response in non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease: a retrospective cohort analysis.

BMC Pulm Med. 2025-5-10

[3]
Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry.

Respir Res. 2025-2-28

[4]
Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis.

Ther Adv Respir Dis. 2025

[5]
Interstitial Lung Disease Phenotypes and Predictive Risk Factors in Primary Sjögren's Syndrome.

J Clin Med. 2024-8-22

本文引用的文献

[1]
Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis.

Chest. 2023-12

[2]
Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis.

Eur Respir Rev. 2023-3-31

[3]
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.

Respir Res. 2023-1-9

[4]
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Am J Respir Crit Care Med. 2022-5-1

[5]
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.

Eur Respir J. 2022-10-6

[6]
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.

Respirology. 2022-4

[7]
Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease.

Ann Am Thorac Soc. 2022-6

[8]
Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia?

Lancet. 2021-10-16

[9]
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.

Lancet Respir Med. 2021-5

[10]
When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases.

Eur Respir J. 2021-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索